摘要
目前临床治疗慢性乙型肝炎病毒(HBV)感染已取得一定进展,但现有的一线药物尚不能完全清除HBV共价闭合环状DNA从而彻底清除HBV。靶向治疗能特异性地结合靶点部位,从而阻断病毒入侵、病毒转录和蛋白翻译等,实现精准治疗。本文整理总结HBV生命周期不同阶段的靶点,从靶向病毒进入、靶向共价闭合环状DNA、靶向核心蛋白、靶向乙型肝炎表面抗原释放、靶向病毒转录等角度进行综述,以期为抗HBV感染的药物研发提供思路。
Although some progress had been made in the treatment of chronic hepatitis B virus(HBV)infection,current first-line drugs failed to completely eliminate the covalently closed circular DNA(cccDNA)of HBV so as to completely eliminate HBV.Targeted therapy can specifically bind to the target sites,thereby blocking virus invasion,virus transcription,and protein translation,achieving precise treatment.Therefore,this article summarized and reviewed the targets at different stages of the HBV life cycle from the perspectives of targeting virus entry,targeting ccDNA,targeting core protein,targeting hepatitis B surface antigen(HBsAg)release,and targeting viral transcription,with a view to providing ideas for drug development against HBV infection.
作者
王聃
张乘龙
唐静
邓琴
杨磊
孙强
王艳
WANG Dan;ZHANG Cheng-long;TANG Jing;DENG Qin;YANG Lei;SUN Qiang;WANC Yan(Department of Infection,First People's Hospital of Ziyang,Ziyang SICHUAN 641300,China;Department of Emergency,Suining Central Hospital,Suining SICHUAN 629000,China;Department of Pharmacy,Jianyang People's Hospital,Jianyang SICHUAN 641400,China;Department of Pharmacy,Sichuan Provincial People's Hospital,Chengdu SICHUAN 610000,China)
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2024年第4期241-246,共6页
Chinese Journal of New Drugs and Clinical Remedies
基金
四川省科技厅重点研发项目(2023YFS0110)。
关键词
乙型肝炎病毒
分子靶向治疗
慢性乙型肝炎
药物研发
hepatitis B virus
molecular targeted therapy
chronic hepatitis B
drug development